News Archive
|
16 May. 2018 BIA Separations and Biomay collaborate on production and purification of large DNA plasmidsCollaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application [more] |
|
5 Feb. 2018 Landmark clinical study with grass pollen vaccine BM32 publishedBiomay announces that the landmark study intitled "Safety and efficacy of immunotherapy with the recombinant B-cell epitope based grass pollen vaccine BM32" has recently been published online in the prestigious Journal...[more] |
|
26 Jan. 2017 Biomay AG reports positive results from a second Phase IIb trial with the innovative 3rd generation grass pollen allergy vaccine BM32Biomay, a global leader in allergy immunotherapy, announced today that a second phase IIb study (clinicaltrials.gov identifier NCT02643641) has been successfully completed with its third generation grass pollen allergy vaccine...[more] |
|
6 Dec. 2016 Biomay Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation AwardBiomay announces that the company has been named one of the winners of the Corporate LiveWire 2016 Healthcare and Life Sciences Awards in the category Best in Allergy Therapeutics Developments. "We are delighted that our...[more] |
|
4 Feb. 2016 Biomay has been granted U.S. patent for peptide carrier fusion allergy vaccinesBiomay announced today that the company received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the composition and use of allergy vaccines based on its innovative...[more] |
|
28 Jan. 2016 Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32Biomay announced today that a new phase II trial with its innovative grass pollen allergy vaccine BM32 based on the proprietary peptide carrier protein platform has been initiated. The aim of the study is the optimization of...[more] |
|
3 Sep. 2015 Fresenius Medical Care releases new adsorber IgEnio® in Europe for treatment of severe allergic symptomsFresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market. Latest epidemiological data shows that IgE-mediated diseases affect more than 25...[more] |
|
3 Jun. 2015 Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conferenceBiomay, a global leader in allergy immunotherapy, announced today that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona,...[more] |
|
28 Jan. 2015 Biomay AG reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32Biomay, a global leader in allergy immunotherapy, announced today that a landmark phase IIb study (clinicaltrials.gov identifier NCT1538979) has been successfully completed with its 3rd generation grass pollen allergy vaccine...[more] |
|
4 Sep. 2014 Biomay AG completes capital increase in the amount of €2.8 million from existing investorsBiomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding...[more] |
Biomay AG completes capital increase in the amount of €2.8 million from existing investors
Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development. Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“. About Biomay: Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com